Amino Acid PET in Neurooncology

The Journal of Nuclear Medicine

article

Norbert Galldiks¹  Philipp Lohmann²  Gereon R. Fink¹  Karl-Josef Langen² 

[1] Department of Neurology, Faculty of Medicine, University Hospital Cologne, University of Cologne;Institute of Neuroscience and Medicine, Research Center Juelich;Center for Integrated Oncology, Universities of Aachen;Department of Nuclear Medicine, RWTH University Hospital Aachen

关键词: FET;    MET;    FDOPA;    fluciclovine;   

DOI  :  10.2967/jnumed.122.264859

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

For decades, several amino acid PET tracers have been used to optimize diagnostics in patients with brain tumors. In clinical routine, the most important clinical indications for amino acid PET in brain tumor patients are differentiation of neoplasm from nonneoplastic etiologies, delineation of tumor extent for further diagnostic and treatment planning (i.e., diagnostic biopsy, resection, or radiotherapy), differentiation of treatment-related changes such as pseudoprogression or radiation necrosis after radiation or chemoradiation from tumor progression at follow-up, and assessment of response to anticancer therapy, including prediction of patient outcome. This continuing education article addresses the diagnostic value of amino acid PET for patients with either glioblastoma or metastatic brain cancer.

【 授权许可】

CC BY